860502P

C2 Ceramide (d18:1/2:0)

Avanti Research^™ - A Croda Brand 860502P, powder

• Synonym(e): N-acetoyl-D-erythro-sphingosine
• Empirische Formel (Hill-System): C₂₀H₃₉NO₃
• CAS-Nummer: 195194-58-2
• Molekulargewicht: 341.53
• UNSPSC-Code: 12352211
• NACRES: NA.25

Eigenschaften

• Form: powder
• Verpackung: pkg of 1 × 5 mg (860502P-5mg)
• Hersteller/Markenname: Avanti Research^™ - A Croda Brand 860502P
• Lipid-Typ: sphingolipids
• Versandbedingung: dry ice
• Lagertemp.: −20°C
• SMILES String: OC[C@]([H])(NC(C)=O)[C@]([H])(O)/C=C/CCCCCCCCCCCCC
• InChI: 1S/C20H39NO3/c1-3-4-5-6-7-8-9-10-11-12-13-14-15-16-20(24)19(17-22)21-18(2)23/h15-16,19-20,22,24H,3-14,17H2,1-2H3,(H,21,23)/b16-15+/t19-,20+/m0/s1
• InChIKey: BLTCBVOJNNKFKC-QUDYQQOWSA-N

Beschreibung

Allgemeine Beschreibung

C2 Ceramide (d18:1/2:0) is a short-chain ceramide. In general ceramides are synthesized by de novo pathway from palmitic acid via series of intermediates to ceramidein the presence of dihydroceramide Δ4-desaturase.

Anwendung

C2 Ceramide (d18:1/2:0) has been used to treat protoplasts for reactive oxygen species generation and as an substrate for sphingomyelin synthase 2 enzyme. It is suitable for use as an exogenous supplement in hippocampal cell cultures for the production of 2-hydroxyeicosatetraenoic acid (12-(S)-HETE).

Biochem./physiol. Wirkung

C2 ceramide inhibits the progression of human bronchocarcinoma by modulating the matrix metallopeptidases-2 levels. It also inhibits glioma invasion and induces apoptosis in HT-29 and HCT-116 human colon cancer cells. Treatment of myotubes with C2-ceramide leads to decrease in glucose uptake and glycogen synthesis. C2 along with C6 ceramides induces insulin resistance in myoblastic C2C12 cell line and L6 myotubes.

Verpackung

5 mL Amber Glass Screw Cap Vial (860502P-5mg)

Rechtliche Hinweise

Avanti Research is a trademark of Avanti Polar Lipids, LLC

Sicherheitshinweise

• Lagerklassenschlüssel: 11 - Combustible Solids
• WGK: WGK 3